CN103505729B - 一种稳定的狂犬病毒人源抗体组合制剂 - Google Patents
一种稳定的狂犬病毒人源抗体组合制剂 Download PDFInfo
- Publication number
- CN103505729B CN103505729B CN201310197288.1A CN201310197288A CN103505729B CN 103505729 B CN103505729 B CN 103505729B CN 201310197288 A CN201310197288 A CN 201310197288A CN 103505729 B CN103505729 B CN 103505729B
- Authority
- CN
- China
- Prior art keywords
- ser
- val
- thr
- pro
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
保存条件 | 0周 | 1周 | |||||
1 | 37℃ | 100% | 105% | ||||
2 | 37℃ | 100% | 96% | ||||
3 | 37℃ | 100% | 110% | ||||
4 | 37℃ | 100% | 95% | ||||
5 | 37℃ | 100% | 95% | ||||
6 | 37℃ | 100% | 93% | ||||
7 | 37℃ | 100% | 98% | ||||
8 | 37℃ | 100% | 100% | ||||
9 | 37℃ | 100% | 103% | ||||
10 | 37℃ | 100% | 95% | ||||
保存条件 | 0周 | 3周 | 6周 | 9周 | 12周 | ||
1 | 25℃ | 100% | 106% | 97% | 100% | 97% | |
2 | 25℃ | 100% | 106% | 96% | 102% | 110% | |
3 | 25℃ | 100% | 105% | 107% | 96% | 103% | |
4 | 25℃ | 100% | 100% | 95% | 104% | 96% | |
5 | 25℃ | 100% | 95% | 98% | 93% | 95% | |
6 | 25℃ | 100% | 98% | 98% | 100% | 80% | |
7 | 25℃ | 100% | 97% | 97% | 106% | 93% | |
8 | 25℃ | 100% | 106% | 103% | 100% | 97% | |
9 | 25℃ | 100% | 97% | 102% | 102% | 97% | |
10 | 25℃ | 100% | 110% | 95% | 95% | 95% | |
保存条件 | 0月 | 1月 | 2月 | 3月 | 6月 | 12月 | |
1 | 2-8℃ | 100% | 105% | 107% | 97% | 97% | 110% |
2 | 2-8℃ | 100% | 98% | 103% | 100% | 100% | 105% |
3 | 2-8℃ | 100% | 102% | 95% | 97% | 100% | 96% |
4 | 2-8℃ | 100% | 110% | 107% | 100% | 93% | 95% |
5 | 2-8℃ | 100% | 95% | 97% | 96% | 97% | 105% |
6 | 2-8℃ | 100% | 102% | 97% | 93% | 89% | 85% |
7 | 2-8℃ | 100% | 104% | 104% | 96% | 95% | 100% |
8 | 2-8℃ | 100% | 107% | 95% | 102% | 96% | 100% |
9 | 2-8℃ | 100% | 96% | 100% | 98% | 95% | 96% |
10 | 2-8℃ | 100% | 103% | 105% | 96% | 96% | 110% |
实施例 | 保存条件 | 0周 | 1周 | ||||
1 | 37℃ | 100% | 99.7% | ||||
2 | 37℃ | 99.9% | 99.7% | ||||
3 | 37℃ | 100% | 99.5% | ||||
4 | 37℃ | 99.0% | 98.7% | ||||
5 | 37℃ | 99.5% | 99.3% | ||||
6 | 37℃ | 99.1% | 98.2% | ||||
7 | 37℃ | 100% | 99.5% | ||||
8 | 37℃ | 99.2% | 98.9% | ||||
9 | 37℃ | 99.4% | 99.1% | ||||
10 | 37℃ | 99.7% | 99.2% | ||||
实施例 | 保存条件 | 0周 | 3周 | 6周 | 9周 | 12周 | |
1 | 25℃ | 100% | 99.5% | 99.7% | 99.3% | 99.3% | |
2 | 25℃ | 99.9% | 99.9% | 99.5 | 98.8% | 99.2% | |
3 | 25℃ | 100% | 99.7% | 99.6% | 99.5% | 99.2% | |
4 | 25℃ | 99.0% | 99.1% | 99.3% | 99.3% | 99.0% | |
5 | 25℃ | 99.5% | 99.4% | 99.3% | 99.1% | 98.5% | |
6 | 25℃ | 99.1% | 98.5% | 98.7% | 98.3% | 97.8% | |
7 | 25℃ | 100% | 99.5% | 99.3% | 99.4% | 99.3% | |
8 | 25℃ | 99.2% | 99.2% | 98.9% | 98.5% | 98.7% | |
9 | 25℃ | 99.4% | 99.5% | 99.1% | 98.7% | 98.5% | |
10 | 25℃ | 99.7% | 99.3% | 99.5% | 99.2% | 98.9% | |
实施例 | 保存条件 | 0月 | 1月 | 2月 | 3月 | 6月 | 12月 |
1 | 2-8℃ | 100% | 99.8% | 99.5% | 99.6% | 99.3% | 99.3% |
2 | 2-8℃ | 99.9% | 99.9% | 99.7% | 99.6% | 99.4% | 99.3% |
3 | 2-8℃ | 100% | 99.6% | 99.6% | 99.7% | 99.5% | 99.4% |
4 | 2-8℃ | 99.0% | 99.2% | 98.9% | 99.1% | 98.7% | 98.5% |
5 | 2-8℃ | 99.5% | 99.1% | 98.9% | 98.6% | 98.8% | 98.4% |
6 | 2-8℃ | 99.1% | 99.2% | 98.8% | 98.2% | 97.8% | 96.8% |
7 | 2-8℃ | 100% | 99.8% | 99.5% | 99.6% | 99.3% | 99.1% |
8 | 2-8℃ | 99.2% | 99.4% | 99.1% | 98.7% | 98.7% | 98.8% |
9 | 2-8℃ | 99.4% | 99.3% | 98.9% | 99.1% | 98.8% | 98.6% |
10 | 2-8℃ | 99.7% | 99.7% | 99.5% | 99.1% | 99.3% | 99.2% |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310197288.1A CN103505729B (zh) | 2013-05-24 | 2013-05-24 | 一种稳定的狂犬病毒人源抗体组合制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310197288.1A CN103505729B (zh) | 2013-05-24 | 2013-05-24 | 一种稳定的狂犬病毒人源抗体组合制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103505729A CN103505729A (zh) | 2014-01-15 |
CN103505729B true CN103505729B (zh) | 2015-10-28 |
Family
ID=49889498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310197288.1A Active CN103505729B (zh) | 2013-05-24 | 2013-05-24 | 一种稳定的狂犬病毒人源抗体组合制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103505729B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104804083B (zh) * | 2015-04-27 | 2019-03-05 | 华北制药集团新药研究开发有限责任公司 | 一种鼠源单克隆抗体及其制备方法和用途 |
CN104829724B (zh) * | 2015-04-27 | 2019-01-11 | 华北制药集团新药研究开发有限责任公司 | 一种鼠源单克隆抗体及其制备方法和用途 |
CN111888470A (zh) * | 2020-08-12 | 2020-11-06 | 赵静 | 具有中和狂犬病病毒效能的冲洗液及其活性检测方法 |
CN114748618A (zh) * | 2022-04-02 | 2022-07-15 | 重庆智翔金泰生物制药股份有限公司 | 包含针对狂犬病病毒g蛋白的双特异性抗体的药物制剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101337990A (zh) * | 2008-06-25 | 2009-01-07 | 中国人民解放军军事医学科学院微生物流行病研究所 | 人源抗狂犬病毒中和性抗体及其制备方法与用途 |
CN101410137A (zh) * | 2006-03-28 | 2009-04-15 | 霍夫曼-拉罗奇有限公司 | 抗-igf-1r人单克隆抗体制剂 |
CN101812131A (zh) * | 2010-05-06 | 2010-08-25 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗狂犬病毒糖蛋白中和性抗体(RVFab8) |
CN101812130A (zh) * | 2010-05-06 | 2010-08-25 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗狂犬病毒糖蛋白中和性抗体(RVFab5) |
-
2013
- 2013-05-24 CN CN201310197288.1A patent/CN103505729B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101410137A (zh) * | 2006-03-28 | 2009-04-15 | 霍夫曼-拉罗奇有限公司 | 抗-igf-1r人单克隆抗体制剂 |
CN101337990A (zh) * | 2008-06-25 | 2009-01-07 | 中国人民解放军军事医学科学院微生物流行病研究所 | 人源抗狂犬病毒中和性抗体及其制备方法与用途 |
CN101812131A (zh) * | 2010-05-06 | 2010-08-25 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗狂犬病毒糖蛋白中和性抗体(RVFab8) |
CN101812130A (zh) * | 2010-05-06 | 2010-08-25 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗狂犬病毒糖蛋白中和性抗体(RVFab5) |
Non-Patent Citations (1)
Title |
---|
pH 值对重组人源抗狂犬病病毒单克隆抗体稳定性的影响;李耿等;《中国生物制品学杂志》;20090930;第22卷(第9期);第891-895页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103505729A (zh) | 2014-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007328960B2 (en) | Liquid anti-rabies antibody formulations | |
RU2664736C2 (ru) | Фармацевтическая композиция, содержащая адалимумаб | |
CN103505729B (zh) | 一种稳定的狂犬病毒人源抗体组合制剂 | |
KR20140079491A (ko) | 당과 폴리올과의 배합물로 안정화된 에타너셉트 제형 | |
AU2008225501B2 (en) | Lyophilized preparation comprising influenza vaccine, and method for preparation thereof | |
JP2019509311A5 (zh) | ||
de Castro et al. | Vaccination with chimeric protein induces protection in murine model against ascariasis | |
JP7467438B2 (ja) | 抗rsv抗体の製剤及びその使用方法 | |
AU2020302077C1 (en) | Compositions and methods for treatment of fungal infections | |
US20090130103A1 (en) | Purification and protective efficacy of monodisperse and modified yersinia pestis capsular f1-v antigen fusion proteins for vaccination against plague | |
US20170073375A1 (en) | Enhanced influenza hemagglutinin binders | |
KR101699244B1 (ko) | 박테리오파지 리신 단백질들의 안정성을 개선할 수 있는 조성물 | |
JP2023087090A (ja) | SseJタンパク質を用いたサルモネラワクチン | |
CN107693796B (zh) | Peg定点修饰的门冬酰胺酶注射剂 | |
ES2602275T3 (es) | Formulaciones líquidas de anticuerpo anti-rabia | |
CN115518151A (zh) | 一种人类免疫缺陷病毒中和抗体制剂及其用途 | |
EP4232067A1 (en) | Granulocyte macrophage-colony stimulating factor mutants | |
EP4331571A1 (en) | Formulations of ace2-igm fusion proteins | |
MX2017013995A (es) | Formulacion farmaceutica estable de una proteina de fusion. | |
KR20140134633A (ko) | 박테리오파지 리신 단백질들의 안정성을 개선할 수 있는 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Wei Jingshuang Inventor after: Wang Cha Inventor after: Jiang Yifan Inventor after: Cao Jiabin Inventor after: Zhang Bin Inventor after: Zhao Junwei Inventor after: Gao Jian Inventor after: Duan Baoling Inventor after: Wang Hui Inventor after: Kong Lingfeng Inventor after: Cheng Lijun Inventor after: Chen Chen Inventor after: Zhao Wei Inventor after: Lv Ruoyun Inventor after: Liu Xiangyi Inventor after: Zhang Shixiong Inventor before: Wei Jingshuang Inventor before: Jiang Yifan Inventor before: Gao Jian Inventor before: Duan Baoling Inventor before: Wang Hui Inventor before: Kong Lingfeng Inventor before: Cheng Lijun Inventor before: Zhao Wei Inventor before: Lv Ruoyun Inventor before: Liu Xiangyi Inventor before: Zhang Shixiong Inventor before: Wang Cha |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WEI JINGSHUANG WANG HUI KONG LINGFENG CHENG LIJUN ZHAO WEI LV RUOYUN LIU XIANGYI ZHANG SHIXIONG WANG CHA JIANG YIFAN GAO JIAN DUAN BAOLING TO: WEI JINGSHUANG WANG HUI KONG LINGFENG CHENG LIJUN CHEN CHEN ZHAO WEI LV RUOYUN LIU XIANGYI ZHANG SHIXIONG WANG CHA JIANG YIFAN CAO JIABIN ZHANG BIN ZHAO JUNWEI GAO JIAN DUAN BAOLING |
|
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Wei Jingshuang Inventor after: Wang Cha Inventor after: Jiang Yifan Inventor after: Cao Jiabin Inventor after: Zhang Bin Inventor after: Zhao Junwei Inventor after: Gao Jian Inventor after: Duan Baoling Inventor after: Wang Hui Inventor after: Kong Lingfeng Inventor after: Cheng Lijun Inventor after: Chen Chen Inventor after: Zhao Wei Inventor after: Lv Ruoyun Inventor after: Liu Xiangyi Inventor after: Zhang Shixiong Inventor before: Wei Jingshuang Inventor before: Wang Cha Inventor before: Jiang Yifan Inventor before: Cao Jiabin Inventor before: Zhang Bin Inventor before: Zhao Junwei Inventor before: Gao Jian Inventor before: Duan Baoling Inventor before: Wang Hui Inventor before: Kong Lingfeng Inventor before: Cheng Lijun Inventor before: Chen Chen Inventor before: Zhao Wei Inventor before: Lv Ruoyun Inventor before: Liu Xiangyi Inventor before: Zhang Shixiong |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |